Agios Pharmaceuticals, Inc. (AGIO)
Nasdaq: AGIO · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2008
Who owns Agios Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
7
Farallon Capital Management, L.L.C. holds 9.9% of Common Stock, par value $0.001 per share (the "Shares"), as its SCHEDULE 13G/A filed Aug 3, 2026 says.
Directors and officers
16
report now, of 35 people on the record since 2013. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 7 named at left.
Holders of 5% or moreshare of the class, as filed
Farallon Capital Management, L.L.C.
SCHEDULE 13G/A · filed Aug 3, 2026 · Common Stock, par value $0.001 per share (the "Shares")
Dapice Joshua J.
SCHEDULE 13G/A · filed Feb 9, 2026 · Common Stock, par value $0.001 per share (the "Shares") · 9.9% in Feb 4, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 17, 2025 · Common Stock
State Street Corporation
SCHEDULE 13G · filed Feb 9, 2026 · COMMON STOCK
Vanguard Capital Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
D. E. Shaw & Co., L.P.
SCHEDULE 13G · filed Jul 2, 2026 · Common Stock, Par Value $0.001 per share
Lynx1 Capital Management LP
SCHEDULE 13G · filed May 6, 2026 · Common Stock, par value $0.001 per share
Paradigm BioCapital Advisors LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.001 par value per share · reported falling below 5%, from 5.2% in Aug 28, 2025
Armistice Capital, LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, Par Value $0.001 per share · reported falling below 5%, from 5.21% in Feb 17, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
Bellevue Group AG
SCHEDULE 13G/A · filed Dec 5, 2025 · Common Stock · reported falling below 5%, from 6.1% in Jul 7, 2025
BB Biotech AG
SCHEDULE 13G/A · filed Jun 13, 2025 · Common Stock · reported falling below 5%, from 6.2% in Feb 14, 2025
What AGIO reports owning in othersstakes of 5% or more, and other ties
7 subsidiaries in 7 countries, from the list filed with the 10-K filed Feb 12, 2026.
Insider tradesForm 4
43sales
0purchases
42sales on a scheduled plan
8people selling
$5.0Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 28, 2025 to Oct 28, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 28, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 39 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Gheuens Sarah | Chief Medical Officer | 12 | $1.9M | 12 | 0 | $0 |
| Goff Brian | Chief Executive Officer | 7 | $1.7M | 7 | 0 | $0 |
| Milanova Tsveta | Chief Commercial Officer | 5 | $400,000 | 5 | 0 | $0 |
| Jones Cecilia | Chief Financial Officer | 6 | $300,000 | 6 | 0 | $0 |
| Burns James William | Chief Legal Officer | 6 | $300,000 | 6 | 0 | $0 |
| Viswanadhan Krishnan | Chief Strategy and Operations | 2 | $200,000 | 2 | 0 | $0 |
| Washburn Theodore James Jr. | Principal Accounting Officer | 4 | $200,000 | 3 | 0 | $0 |
| Scadden David | director | 1 | $0 | 1 | 0 | $0 |